<DOC>
	<DOCNO>NCT01546506</DOCNO>
	<brief_summary>Rationale : Classical antiviral therapy target viral protein consequently subject resistance . To counteract limitation , alternative strategy develop target cellular factor . We hypothesize approach could also useful identify broad-spectrum antiviral . The influenza A virus use model viral diversity need develop therapy unpredictable virus recently underline H1N1 pandemic . Gene-expression signature-based screening identify broadly effective influenza A antiviral . Midodrine show great result inhibit viral growth suit confirm efficacy vivo . The main objective study assess efficacy midodrine take usual recommend dose ( 7.5mg/day ) versus treatment viral replication kinetics virus Influenza A . Secondary objective : evaluation number patient normalized viral load 2 , 3 5 7 day post-treatment ; description anti-viral efficacy midodrine define delay obtain prolonged negativity viral RNA ; description tolerance midodrine , evaluation clinical response study treatment ; evaluation dynamic viral replication ; analysis frequency emergence mutant associate resistance . Methods : This multicenter , randomize , open-label study compare patient age 18 65 year infect influenza A virus . Nasopharyngeal wash perform day 0 ( randomization ) , 2 , 3 , 5 show viral replication evolution . 161 patient randomized follow : - Arm 1 : Midodrine , 2.5 mg , 3 time day - Arm 2 : No treatment The recruitment perform general practitioner Lyon area .</brief_summary>
	<brief_title>Confirmation Antiviral Effects Midodrine Identified With Gene Expression Signature-based Screening Inluenza A Virus Infected Cells</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>men woman age 18 65 year , longterm illness , present flulike symptom less 42 hour ( nasal congestion , sore throat , muscle soreness , asthenia , headache , chills/sweating , fever… ) , infection influenza A virus confirm quick diagnostic test , outpatient care , must provide sign informed consent , beneficiary health insurance . severe form flu , pregnant woman positive pregnancy test , breastfeed woman , woman childbearingpotential efficient contraceptive , history chronic respiratory disease : asthma chronic obstructive pulmonary disease , renal failure , Raynaud 's disease , history epilepsy , confusion , hallucination psychoneurotic state , patient increase cardiovascular risk ( &gt; 20 % accord Framingham scale ) cardiovascular history , patient congestive heart failure , swollen legs posture hypotension , patient receive influenza vaccine season 20112012 20122013 , know hypersensitivity component treatment , topical use nasal decongestant ( except physiological serum ) , use steroid , immunosuppressive antipsychotic drug ( include treatment nausea ) , use indirect sympathomimetics drug ( ephedrine , methylphenidate , phenylephrine , pseudoephedrine ) , use dopaminergic ergot alkaloid ( bromocriptine , cabergoline , lisuride , pergolide ) vasoconstrictor ergot alkaloid ( dihydroergotamine , ergotamine , methylergométrine , methylsergide ) , know hypertension treat , history bradycardia , history urinary retention , severe cardiopathy , acute angleclosure glaucoma , severe obliterative vasculopathy , vasospasm , thyrotoxicosis , pheochromocytoma , history angina pectoris , use guanethidine relate , iproniazide ( non selective MAOIs ) , alphablockers digitalis drug use neuraminidase inhibitor : oseltamivir , zanamivir ; M2 protonselective ion channel inhibitor : amantadine rimantadine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>